Compare FXNC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | AKBA |
|---|---|---|
| Founded | 1907 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.4M | 248.3M |
| IPO Year | 2012 | 2014 |
| Metric | FXNC | AKBA |
|---|---|---|
| Price | $29.86 | $0.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $32.50 | $3.92 |
| AVG Volume (30 Days) | 15.1K | ★ 7.5M |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ 96.00 | 93.94 |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $5.70 | N/A |
| Revenue Next Year | $4.38 | N/A |
| P/E Ratio | $25.49 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $22.09 | $0.54 |
| 52 Week High | $33.24 | $3.19 |
| Indicator | FXNC | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 18.58 |
| Support Level | $28.72 | N/A |
| Resistance Level | $30.41 | $1.52 |
| Average True Range (ATR) | 0.63 | 0.05 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 58.39 | 2.43 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.